by Isogenica Webmaster | Sep 2024 | Blogs, Case studies
Tools for ADC drug discovery – screening VHHs with pre-engineered C-terminal cysteine handles In the fast-paced world of biotechnology, innovation often stems from taking smart, calculated risks. At Isogenica, we are used to running unusual antibody drug discovery...
by Isogenica Webmaster | Jun 2024 | Blogs, Case studies
Appetite for destruction: ‘Plug and play’ targeted protein degradation using synthetic VHH antibodies to take out tricky targets A recent study demonstrating the effectiveness of single domain antibody-directed protein degradation adds to this new and expanding...
by Isogenica Webmaster | Jun 2024 | Blogs, Case studies, Intrabodies blog
‘Intrabodies’ – Isogenica’s VHH antibodies improve heart function when delivered intracellularly Our VHH antibodies have been put to the test as a potential new therapy for heart failure in an early-stage study from AstraZeneca published in...
by Isogenica Webmaster | May 2024 | Blogs, Case studies
2-for-1 VHH antibody engineering Humanising and improving antibody affinity all in one step Sometimes the smallest of molecules pose the greatest challenges. This was the case when a partner approached us with what turned out to be a VHH antibody engineering...